CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving...(eding manifestationsmake their appearanc...)

The incidence of hemophilia A is one in 10,000 live male births. Women may also have it, but it is very rare. With treatment and management, the outcome is good and the majority of patients suffering from hemophilia are able to lead relatively normal lives.

Von Willebrand disease (VWD) is caused by a deficiency or abnormality of the von Willebrand factor, a protein present in the blood which is necessary for normal blood clotting.(i) Men and women are equally likely to be affected by VWD.(i) VWD is classified by types, ranging from Type I (the most common and mild) to Type III (the most severe).

According to the World Federation for Hemophilia, VWD is found in approximately 1-2 percent of the world's population, although that prevalence is much higher in certain countries such as Iran.

Common symptoms of VWD include frequent nosebleeds and easy bruising. It can be mild or serious and can occur as a result of injury, or without any obvious cause.(i) More serious symptoms include bleeding into joints and internal organs. Women with VWD are more likely to experience abundant, prolonged menstruation.

Individuals with the more severe form of VWD should avoid unnecessary trauma, such as those brought on by contact sports. Patients with VWD may require special care during dental procedures, surgery and childbirth.(ii) There is no "cure" for VWD, but it can be treated. Specific treatments may include desmopressin acetate to release stored von Willebrand factor; von Willebrand factor replacement therapies, such as Humate-P(R), Antihemophilic Factor/von Willebrand Factor Complex (Human) Dried, Pasteurized; and oral contraceptives to reduce menstrual bleeding and ra
'/>"/>